2019
Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth
2014
Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
Martin DT, Steinbach JM, Liu J, Shimizu S, Kaimakliotis HZ, Wheeler MA, Hittelman AB, Saltzman W, Weiss RM. Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer. Molecular Cancer Therapeutics 2014, 13: 71-81. PMID: 24222663, PMCID: PMC3924597, DOI: 10.1158/1535-7163.mct-13-0502.Peer-Reviewed Original ResearchConceptsBladder permeability barrierSurvivin siRNAChitosan delivery systemBladder cancerBladder diseaseTherapeutic responseTumor volumeXenograft tumorsMouse bladderTumor siteSurvivin expressionIntravesical deliveryHuman ureterTumor cell uptakeSiRNATumorsUnmodified nanoparticlesCell uptakeDelivery system
2013
A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.
Hoimes C, Martin D, Kaimakliotis H, Cheng C, Kelly W, Tew G, Wheeler M, Weiss R, Saltzman W. A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery. Journal Of Clinical Oncology 2013, 31: e15543-e15543. DOI: 10.1200/jco.2013.31.15_suppl.e15543.Peer-Reviewed Original ResearchBladder cancerUM-UC-3Human ureterProgression of BCNon-invasive bladder cancerInhibition of invasionHDAC inhibitor belinostatFlank xenograftsTumor sizeDisease progressionTumor regressionUrothelial barrierTumor volumeIntravesical drug deliveryMouse bladderBC cellsHDAC inhibitionMurine bladderCell cytotoxicityT24 lineFACS analysisSimilar IC50Three daysFinal treatmentUreter